Cite
MLA Citation
A. Zeidan et al.. “Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING.” Leukemia research, vol. 128, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100184747753.0x00004a